BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2014 3:23:00 PM | Browse: 1419 | Download: 1424
 |
Received |
|
2012-11-13 06:49 |
 |
Peer-Review Started |
|
2012-11-13 19:54 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2012-11-21 16:25 |
 |
Revised |
|
2012-11-26 14:40 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2012-12-24 14:30 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2012-12-25 02:33 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-03-12 10:36 |
 |
Publish the Manuscript Online |
|
2013-03-14 19:50 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Infliximab induces remission in cryptogenic multifocal ulcerous stenosing enteritis: First case
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Heiko De Schepper, Elisabeth Macken, Veerle Van Marck, Maarten Spinhoven, Paul Pelckmans and Tom Moreels |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Heiko De Schepper, MD, Department of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem-Antwerp, Belgium. heiko.de.schepper@uza.be
|
| Key Words |
Cryptogenic multifocal ulcerous stenosing enteritis; Infliximab; Stenosis; Intestinal ulceration; Inflammatory bowel disease |
| Core Tip |
|
| Publish Date |
2013-03-14 19:50 |
| Citation |
Heiko DS, Elisabeth M, Veerle VM, Maarten S, Paul P, Tom M. Infliximab induces remission in cryptogenic multifocal ulcerous stenosing enteritis: First case. World J Gastroenterol 2013; 19(10): 1661-1664 |
| URL |
http://www.wjgnet.com/1007-9327/full/v19/i10/1661.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v19.i10.1661 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.